Prior to cofounding Orbital, Pino served as CSO at Beam Therapeutics (Orbitals strategic partner and also a company with a deep bench of RNA capabilitiesat Beam, base editors are introduced into cells as mRNA!). ClinicalTrials.gov Identifier: NCT05885464, Interventional Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases. Beam Therapeutics Market Cap $2B Today's Change (-3.50%) -$1.17 Current Price $32.21 Price as of May 25, 2023, 4:00 p.m. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. BEAM-102 continues to progress, and the company plans to submit an investigational new drug (IND) application for BEAM-102 for the treatment of SCD in the second half of 2022. Beam Therapeutics is registered under the ticker NASDAQ:BEAM . Before Millennium, he served as director of molecular biology and director of market and business development at Biogen, Inc. At Biogen, Dr. Maraganore invented and led the discovery and development of ANGIOMAX (bivalirudin) for injection, formerly HIRULOG and currently marketed by The Medicines Company. several of the academic foundersin fact, we were also seed investors in CircBio, a technology company that Orbital has now acquired. Dr. Singh has more than 24 years of drug discovery and development experience at Takeda Pharmaceuticals, Novartis and Chiron Corporation. August 09, 2022 06:30 ET Prior to Forma, Dr. Bellon was Senior Vice President of Legal Affairs for Relay Therapeutics, where she helped obtain foundational partnerships for the company and formulated its intellectual property strategy. They embody our spirit, define how we work, and help us rise to the challenge. Dr. Joung holds a Ph.D. in genetics from Harvard University, an M.D. While at these companies, Dr. Enter Orbital Therapeutics, led by CEO Pino Ciaramella. Since joining ARCH in 2002, Ms. Burow has played a significant role in the creation and development of a number of companies. Breaking new ground to advance science with the potential to change lives. From 2002-2016 Fishman was the founding President of the Novartis Institutes for BioMedical Research (NIBR). Prior to Boehringer Ingelheim, he spent 14 years at Pfizer in the UK where he held several Discovery leadership positions, including head of Biotherapeutics, head of Antivirals and head of Lead Discovery. Investors:Chelcie ListerTHRUST Strategic Communicationschelcie@thrustsc.com, Cash, cash equivalents, and marketable securities, Change in fair value of derivative liabilities, Change in fair value of non-controlling equity investments, Change in fair value of contingent consideration liabilities, Net loss per common share, basic and diluted, Weighted-average common shares outstanding, basic and diluted. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. At Novartis, he served as the Head of Formulation Development for more than 10 years and was instrumental in the licensure of several key vaccines (Bexsero , Fluad, Flucelvax) that were subsequently divested to GSK and CSL. Beam Therapeutics Both her doctoral and postdoctoral work culminated in prominent Nature publications in the fields of natural product chemistry and gene editing respectively. During his Ph.D. research with Professor Peter Schultz at U. C. Berkeley, Dr. Liu initiated the first general effort to expand the genetic code in living cells. She then joined the lab of Jacqueline K. Barton at the California Institute of Technology for her doctoral studies. He is currently Desmond and Ann Heathwood Research Scholar, Pathologist, and Associate Chief of Pathology for Research at Massachusetts General Hospital (MGH) and is Professor of Pathology at Harvard Medical School. The field of RNA medicines is now undergoing nothing short of a renaissance. With a strong background across multiple drug modalities including small molecules, biologics and gene therapies, he will bring great experience and leadership to our R&D teams. BEACON Trial of BEAM-101 in Sickle Cell Disease Ongoing with Data from Multiple Patients Expected in 2024; Expansion Phase Initiation Expected in 2023 First Patient Dosing in BEAM-201 Trial in . Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the potential impact of the COVID-19 pandemic; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that enrollment of our clinical trials may take longer than expected; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings Risk Factors Summary and Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2020, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, our Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, and in any subsequent filings with the Securities and Exchange Commission. CAMBRIDGE, Mass., January 24, 2020 Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the promotion of chief scientific officer Giuseppe "Pino" Ciaramella, Ph.D., to president.Dr. BEAM-102 is designed to treat SCD by directly editing the causative HbS point mutation to recreate a naturally occurring normal human hemoglobin variant, HbG-Makassar. Fabricio is passionate about traveling and is a dog lover! John has a deep science background and an extensive track record in the strategic development and commercialization of novel medicines, including cell therapy products, at leading companies. Dr. Manmohan Singh is the Chief Technology Officer at Beam Therapeutics. She brings to Beam more than 25 years of experience in the life science industry. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. These are all special tailwinds for startup foundersespecially those who have been original innovators in the field. Read more. J.P. Morgan Healthcare ConferenceMr. investors@beamtx.com, CAREER INQUIRIES BEAM-301, a liver-targeting lipid nanoparticle (LNP) formulation of base editing reagents designed to correct the R83C mutation, the most common disease-causing mutation of GSDIa, is on track for initiation of IND-enabling studies in the second half of 2022. Dr. Shanker has a proven ability in successfully building, coaching, and developing cross-functional drug discovery teams as well as creating purpose-driven, highly productive research organizations. in Chemistry from Columbia University and a B.S. BEAM-201 is a multiplex base edited anti-CD7 CAR-T cell investigational therapy for relapsed and refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma, a severe disease affecting children and adults. In principle, RNA medicines could transform any cell in a patients body into a protein production factory of our choice. He has also received technology innovation awards from the McKnight, New York Stem Cell, and Damon Runyon foundations. Dr. Shanker joins us after leading Tevard Biosciences, and prior to that, he was with Novartis Institute of Biomedical Research and during his tenure at Novartis, he held multiple key leadership roles including Head of Neuroscience Disease Area, Head of Psychiatry and Neurodevelopmental Disorders, and Head, Ion Channels and Receptors. Keywords provided by Beam Therapeutics Inc.: Why Should I Register and Submit Results? J. Keith Joung is a leading innovator in the field of genome editing. Pfizer is the latest large drug company to move into gene editing, placing a big bet on CRISPR-based therapeutics that can correct single-letter typos in DNA, an approach known as base editing. And prior to this, Pino was CSO of the infectious diseases division at Moderna, where he led the companys initial mRNA vaccine pipeline and first IND submission. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. in Chemistry and Physics from Harvard College and his Ph.D. in Chemistry from Stanford University. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities . At the CRISPR 2.0 conference in June, Beam highlighted research that led to the creation of an improved class of cytosine base editors (CBEs), leveraging a TadA enzyme-based CBE (CBE-T), that are capable of editing at levels comparable to traditional CBEs but with lower off-target editing potential. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05885464, We're building a modernized ClinicalTrials.gov! clinicalinfo@beamtx.com, This website uses cookies. He brought a particular focus on regenerative medicines as treatments for disorders of aging. Dr. Giuseppe Ciaramella is the President of Beam Therapeutics. In addition to his publications in developmental biology and drug discovery, Fishman is the author of the textbook, Medicine, and of Lab, an architecture book on how to design buildings for scientists. Mark C. Fishman, M.D., is Professor in the Harvard Department of Stem Cell and Regenerative Biology and Chief of the Pathways Clinical Service service at the MGH for patients with complex medical disorders. Orbital is taking advantage of what is already known, but also innovating with urgency to make RNA-based therapeutics impactful and accessible for a much wider set of patients worldwide. BM with 5% lymphoblasts by morphologic assessment or evidence of extramedullary disease at screening after second documented CR; OR, Flow cytometric confirmation of relapsed T-ALL of at least 0.1% after second CR documented to have been MRD negative < 0.1%; OR, Any detectable relapsed disease post-allogeneic HSCT with flow cytometric confirmation of T-ALL of at least 0.1%; OR, Biopsy confirmed evidence of relapsed T-LL on lymph node biopsy after second CR; OR, Any detectable disease post-allogeneic transplant with biopsy confirmed evidence of T-LL on lymph node biopsy, Primary refractory T-ALL or T-LL, defined as failure to achieve CR after induction chemotherapy, per investigator assessment and based on biopsy-confirmed evidence of residual T-ALL or T-LL; OR. He also led the development of the LNP platform of Novartiss RNA vaccine. John Maraganore has served as the founding CEO and a director of Alnylam since 2002, where he has built and led the company from early platform research on RNA interference through global approval and commercialization of the first three RNAi medicines including ONPATTRO, GIVLAARI, and OXLUMO. Dr. Ciaramella has more than 20 years of drug discovery experience at Moderna, AstraZeneca, Boehringer Ingelheim, Pfizer and Merck. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We are located at: 238 Main Street, Cambridge, MA 02142. Cambridge Research Triangle Park. He has contributed to several clinical candidates, both small molecule and biologics and to the anti-HIV drug Maraviroc (Selzentry TM), which won the USA Prix Galien for Best Pharmaceutical in 2008. Research Triangle Park in North Carolina is home to our new manufacturing facility. She previously was a co-founder and Director of Receptos (RCPT acquired by Celgene). Beam plans to provide additional updates pending interaction with the FDA. He has received numerous awards including an NIH Directors Pioneer Award, an NIH Directors Transformative Research Project R01 Award, the MGH Research Scholar Award, an NIH R35 MIRA (Maximizing Investigators Research Award), election into the American Association of University Pathologists, and designation as a Highly Cited Researcher in 2016 and 2017 by Thomson Reuters/Clarivate Analytics. Prior to Novartis, Dr. Singh also spent more than 10 years at Chiron Corporation, where he led the development of Novel adjuvants and delivery systems for vaccines. Dr. Gopi Shanker is the Chief Scientific Officer of Beam Therapeutics. Ms. OConnor holds a bachelors degree from Providence College. Further, Beam disclosed an additional editor, CABE-T, that can conduct both C-to-T and A-to-G edits with a single TadA deaminase. If the mission of building the future of RNA medicines excites you, consider joining our Orbit! The Makassar variant has been reported to have the same function as the more common HbA variant and does not cause SCD. BEAM-201 is a multiplex base edited anti-CD7 CAR-T cell investigational therapy designed to treat relapsed/refractory T cell acute lymphoblastic leukemia, a severe disease affecting children and adults. Lo has also helped build strategies and grow R&D pipelines as co-chair of the Development Committee at Celgene, leading to multiple pivotal study investments. Graham Cooper is a member of the boards of directors of other public companies including Unity Biotechnology and Kezar Life Sciences. I am passionate about road racing, and won my class championship in 2021 racing with NASA (National Auto Sport Association). RNA could be used to train our immune system, replace missing proteins, reprogram cells, introduce genetic editors, and much more. None of this would be possible without the commitment of our remarkable team of fearless innovators. Dr. Liu has earned several university-wide distinctions for teaching at Harvard, including the Joseph R. Levenson Memorial Teaching Prize, the Roslyn Abramson Award, and a Harvard College Professorship. Beam; Tubing and Pipe; Bars and Shapes; About. We deeply respect the iterative engineering mindset that the team brings to key goalsthe modular, high-throughput platform built to screen synthetic circular RNAs for extended durability in the Stanford lab of Orbital co-founder Howard Chang is a beautiful example, recognized recently on the cover of Nature Biotechnology (shown below!). She began her career in clinical practice, training as a resident in internal medicine and as a fellow in pulmonary and critical care medicine at Tufts Medical Center. Ms. Walsh holds a B.A. He helped initiate and lead Agios landmark alliance with Celgene, resulting in over $600M of funding and investments across multiple research collaborations in cancer metabolism. Please see https://a16z.com/disclosures for additional important information. BEAM-101 aims to potentially alleviate the effects of mutations causing sickle cell disease (SCD) or beta-thalassemia by leading to increases in fetal hemoglobin, which inhibits hemoglobin S (HbS) polymerization. During his tenure, NIBR discovered and brought through successful clinical trials 90 new medicines in more than 120 indications. Dr. Bellon holds a B.S. BEAM has a market cap of $2.57bn and a cash balance of $1.1bn. Relapsed, refractory disease, defined as > 5% BM blasts or biopsy-confirmed evidence of residual TLL after 1 course of re-induction chemotherapy for patients who have relapsed after previously achieving a CR NOTE: Patients with mixed phenotype acute leukemia with T-cell dominant phenotype may be enrolled if the aforementioned criteria are met. Prior to Beam, Ms. Burrell spent 11 years with J.P. Morgan, most recently as a Managing Director in the healthcare investment banking group. Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. David R. Liu is the Richard Merkin Professor and Vice-Chair of the Faculty at the Broad Institute of Harvard and MIT, Professor of Chemistry and Chemical Biology at Harvard University, and Howard Hughes Medical Institute Investigator. Dr. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. in Chemistry from the University of California, Berkeley. We are located at: 238 Main Street, Cambridge, MA 02142. Every single piece of an RNA medicinefrom the RNA structure, to the regulatory sequences, to the delivery vehicles, to manufacturingis amenable to screening, machine learning, and design optimization to tune in the exact therapeutic properties needed to unlock new clinical applications. Nicole Gaudelli received her B.S. Dr. Fishman graduated from Yale College and Harvard Medical School and trained in medicine and Cardiology at Massachusetts General Hospital. In July, Beam and Verve Therapeutics amended their collaboration and license agreement, originally executed in April 2019. Based on his contributions at Chiron and Novartis, Dr. Singh is considered as one of the leading experts in the field of adjuvants and vaccine delivery systems. Beam's stock was up 4.9% before the market . (For other examples, think of the PC market after IBM; the biotech sector after Genentech pioneered the use of recombinant DNA; the field of AAV gene therapy following work done at CHOP/Spark towards a first approval; or most recently, the field of startups advancing generative AI applications after OpenAIs launch of GPT-4.) Dr. Gaudelli is an inventor on numerous base editing patents and leads the gene editing technologies platform group at Beam Therapeutics where her team advances precision genetic medicines using base editors. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company (Pharmaceuticals practice) and MedImmune. There, he helped to cultivate the companys biologics business, managing five biologics plants supporting the companys drug substance and products across North America and Europe. Dr. Ho has more than 15 years of life sciences experience as a clinical neurologist, neuroscientist and leader in biopharmaceutical drug development. Furthermore, this content is not directed at nor intended for use by any investors or prospective investors, and may not under any circumstances be relied upon when making a decision to invest in any fund managed by a16z. In the 1990s, by harnessing the first large-scale genetic screens in zebrafish (performed in collaboration with W. Driever and contemporaneously with C. Nuesslein-Volhard), and by providing much of the early genomic infrastructure, Fishmans lab helped to make the zebrafish a cornerstone of developmental biology, and led to revelation of many of the pathways that guide vertebrate organ development, particularly the heart and vessels. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release. Your Beam Pros. R83C is the most common disease-causing mutation of GSDIa, a life-altering genetic disease with no approved disease-modifying treatments available today. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. careers@beamtx.com, CLINICAL TRIAL INQUIRIES Dr. Komor joined the Department of Chemistry and Biochemistry at the University of California at San Diego in 2017, where her lab develops and applies new precision genome editing techniques to the functional genomics field. from Harvard Medical School and an A.B. (currently inactive). He played a seminal role in developing optogenetics, a powerful technology for dissecting neural circuits using light. RNA medicines could be programmable, personalizable, and yeseven printed at record speed. Dr. Zhang is a bioengineer developing and applying novel molecular technologies for studying the molecular and genetic basis of diseases and providing treatment. Her expertise includes overall talent management, culture building, strategic recruitment and selection, IPO planning and execution, leadership development as well as board development and engagement. These are an incredibly exciting set of engineering biology challenges to tackle. Dr. Simon brings more than 20 years of clinical experience to Beam, serving in roles as a physician-scientist in academia and the biotechnology industry. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the potential impact of the COVID-19 pandemic, including its impact on the global supply chain; the uncertainty that our product candidates, including BEAM-201, will receive regulatory approval necessary to initiate human clinical studies; uncertainty in the FDAs plans to communicate and discuss the clinical hold on the BEAM-201 IND with us and the risk that those discussions may be delayed; the uncertainty in the outcome of our interactions with the FDA regarding the clinical hold on the BEAM-201 IND; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that enrollment of our clinical trials may take longer than expected; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings Risk Factors Summary and Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2021, and in any subsequent filings with the Securities and Exchange Commission. CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in fireside chats during the following May . Prior to Catalent, Mr. Riley served as the Site Director of Durham, NC operations at bioMerieux, where he led both the companys compliance remediation effort and global growth platform. degree in biochemistry from Boston College in 2006 where she studied the structural and mechanistic underpinnings of neocarzinostatin biosynthesis and a non-heme iron oxygenase involved in vancomycin assembly. Information provided by (Responsible Party): This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. He is also a member of the Center for Cancer Research and the Center for Computational and Integrative Biology at MGH. R&D expenses were $99.6 million for the first quarter of 2023, while G&A expenses were $23.5. We believe we are well positioned today, with four development candidates, a rich pipeline of earlier stage programs, and an industry-leading platform of editing and delivery technologies enabling us to bring forward a new class of precision genetic medicines. She is a trustee of the Boston Museum of Science. | Beam Therapeutics, launched in 2018, is pioneering the . Dr. GENERAL INQUIRIES Beam Therapeutics, First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in the Second Half of 2022, BEAM-301 Named as Fourth Development Candidate for the Treatment of Glycogen Storage Disease Type Ia, Nomination of Two Additional Development Candidates Anticipated in 2022, Company to Present Pipeline and Business Updates at 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 2:15 p.m. Dr. Zhang received his A.B. Pino is an exceptional example of a founding CEO (a profile we love to back!) He has published more than 150 papers and is the inventor of more than 50 issued patents. Prior to her tenure at MGH, she held positions in a number of New York City hospitals including Montefiore, Columbia Presbyterian Medical Center, Saint Lukes Roosevelt Hospital Center and the New York City Health and Hospitals Corporation. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. A live webcast will be available in the investor section of the companys website at www.beamtx.com and will be archived for 60 days following the presentation. Susan OConnor is an accomplished executive with progressive and diversified experience in the biotechnology sector. Prior to Beam, Ms. OConnor launched OConnor & Associates, a strategic human resources consulting firm, in 2008. Mr. Riley holds an MBA from Campbell University and a B.S. Beam continues to anticipate the nomination of a second liver-targeted development candidate in 2022. As often happens following fundamental technology breakthroughs in any field, we now see the pace of innovation in RNA medicines accelerating even further. Prior to her appointment at BMC, Ms. Walsh served as Executive Vice President and Chief Operating Officer of Brigham and Womens Hospital. Following early wins in the field, dozens of universities have created dedicated centers for RNA biology and therapeutics. The stock has fallen by -17.23% since the beginning of the year, thereby showing the potential of a further growth. Beam Therapeutics Prior to joining Beam Therapeutics, Dr. Ciaramella was the CSO of the Infectious Diseases division of Moderna Therapeutics, where he was instrumental in generating some of the first mRNA vaccines to be dosed in humans, several of which are progressing through clinical studies. Beam plans to nominate a second CAR-T development candidate in 2022. Beams suite of gene editing technologies is anchored by base editing, a proprietary technology that enables precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. Katalin Karik and Drew Weissman (Orbital Therapeutics co-founder) were recognized with a 2021 Lasker Award for discovering mRNA modifications that avoid immune activation and improve protein production efficiency. Dr. T-ALL/T-LL that is CD7-positive (defined as at least 20% of blasts positive for CD7 by flow cytometry or immunohistochemistry based on assessment of the study site's CLIA [Clinical Laboratory Improvement Amendments of 1988] certified facility) in second or greater relapse, first relapse post-transplant relapse, or chemotherapy-refractory disease. She is a member of the boards of the Federal Reserve Bank of Boston, the Boston Public Health Commission, the Massachusetts Hospital Association, the AAMC Council of Teaching Hospitals, Pine Street Inn, and Yale University. We are on track to further expand our portfolio with a steady cadence of clinical and preclinical milestones expected in the quarters ahead, including the IND submission for BEAM-102, our second program in sickle cell disease, and the initiation of IND-enabling studies for BEAM-301, our first liver-directed base editing program in glycogen storage disease, both targeted in the second half of this year., Mr. Evans added, As pioneers and leaders in the field of base editing, weve continued to extend the potential reach of our base editing technology and applications with the development of new base editors, as well as novel base editing-enabled therapeutic strategies, such as our work on non-genotoxic conditioning to improve transplant regimens. She was previously a Senior Director of Business Development at Celgene Corporation, where she was responsible for leading collaborations, licensing transactions, equity investments, and mergers and acquisitions across a variety of therapeutic areas. is Chief Medical Officer of Beam. in History and Science from Harvard University, and an M.D. Mr. Cooper is focused on financial operations and capital markets strategy. In addition, this content may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. Dr. Liu became a Howard Hughes Medical Institute Investigator in 2005 and joined the JASONs, academic science advisors to the U.S. government, in 2009. While at Caltech, she worked as an NSF Graduate Research Fellow on the design, synthesis, and study of DNA mismatch-binding metal complexes and received her Ph.D. in 2014. Ms. Wallace holds an A.B. The amended agreement returned two targets to Beam, while adding a new, third target toward an additional liver-mediated, cardiovascular disease target. For general information, Learn About Clinical Studies. from Columbia Law School. The fact that proteins are not synthesized directly on genes demands the existence of an intermediate information carrierwhich receives genetic information from the gene in the form of an unstable intermediatea special type of RNA molecule, or messenger RNA., Brenner, Jacobson, and Meselson et al, Nature, 1961. Prior to joining Celgene, Ms. Wallace was a consultant with Easton Associates (now part of Navigant Consulting), a boutique healthcare management consultancy. Delivery modality: Electroporation | Ex vivo. Individual Participant Data (IPD) Sharing Statement: Studies a U.S. FDA-regulated Drug Product: Studies a U.S. FDA-regulated Device Product: 36 patients in the Phase 1 dose exploration, approximately 12 patients in the Phase 1 dose-expansion cohorts. Feng Zhang is a core institute member of the Broad Institute of MIT and Harvard, an investigator at the McGovern Institute for Brain Research at MIT, and the James and Patricia Poitras Professor in Neuroscience at MIT. He performed synthetic organic and bioorganic chemistry research on sterol biosynthesis under Professor E. J. Coreys guidance as an undergraduate. Dr. Liu is the scientific founder or co-founder of several biotechnology and therapeutics companies, including Ensemble Therapeutics, Permeon Biologics, Editas Medicine, Pairwise Plants, and Beam Therapeutics. With more than 25 years of experience in human resources, she has made significant contributions in building and leading companies from the initial startup phase and scaling through commercialization. During her eight-year tenure at Genentech, she held positions of increasing responsibility across both the early and late stage clinical development groups with development oversight for multiple therapeutic areas and molecules including crenezumab for Alzheimers disease, lampalizumab for dry age related macular degeneration, and development activities leading to the approvals of ocrelizumab for multiple sclerosis and Rituxan for Wegeners granulomatosis and microscopic polyangiitis. Lo has successfully launched numerous drugs in the US and globally, including Tagrisso in lung cancer and two cell therapies. Lo joins Beam after serving as an advisor to multiple private- and public-stage biotechnology companies, including Beam. We speak with Jefferies' Mike Yee, Denali Therapeutics' Ryan Watts, and Dr. Rachita Sumbria of Chapman University. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Beam Therapeutics | 43,618 followers on LinkedIn. A list of investments made by funds managed by Andreessen Horowitz (excluding investments for which the issuer has not provided permission for a16z to disclose publicly as well as unannounced investments in publicly traded digital assets) is available at https://a16z.com/investments/. First-generation RNA medicines discharged a series of existential risks, including scaled RNA synthesis, delivery past the lipid bilayer, protection from RNA-degrading enzymes, and avoidance of immunogenicity. Lymphodepletion regimen including fludarabine, cyclophosphamide and alemtuzumab, A single dose of BEAM-201 administered by IV following one of two lymphodepletion regimens, Lymphodepletion regimen without Alz but consisting of the same dose of Flu/Cy as in the other arm. investors@beamtx.com, CAREER INQUIRIES I am passionate about family, reading and collecting Hard Rock T-shirts around the US and the world. The Phase 1/2 study will test BEAM-101, a therapy designed to treat sickle . A team united by a passion to innovate. Dr. February 14, 2022 . Read more. in English with distinction from Yale University. The trial is expected to include an initial sentinel cohort of three patients, treated one at a time to confirm successful engraftment, followed by dosing in up to a total of 45 patients. Investors:Chelcie ListerTHRUST Strategic Communicationschelcie@thrustsc.com. GENERAL INQUIRIES From 1999 to 2006, Mr. Cooper held positions of increasing responsibility including Director of Healthcare Investment Banking at Deutsche Bank Securities, where he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field. Incidence and severity of treatment-emergent adverse events (TEAEs) and treatment-related adverse events, including serious adverse events (SAEs) and dose-limiting toxicities (DLTs; in Phase 1 only) [TimeFrame:Through study completion, an average of 25 months], Overall response rate as defined as proportion of T-ALL patients achieving complete response (CR) or complete response with incomplete hematologic recovery (CRi) or T-LL patients achieving CR or PR at any point after BEAM-201 infusion [TimeFrame:From treatment with BEAM-201 through study completion], Proportion of patients who achieve MRD negative response (defined as < 0.1%) by flow cytometry or next generation sequencing (NGS) in patients achieving morphologic response [TimeFrame:Starting at Day 28 and multiple time points up to Month 24], Proportion of patients treated with BEAM-201 deemed appropriate for HSCT based on investigator assessment of clinical response [TimeFrame:Through study completion, an average of 25 months], Duration of Response (DOR) [TimeFrame:Through study completion, an average of 25 months], Relapse-free survival (RFS) [TimeFrame:Through study completion, an average of 25 months], Overall survival [TimeFrame:Through study completion, an average of 25 months], Relapse-related mortality [TimeFrame:Through study completion, an average of 25 months]. We are located at: 10 Davis Drive, Durham, North Carolina 27709. The FDA indicated it will provide an official clinical hold letter to Beam within 30 days. Sign up for our bio newsletter to get the a16z take on the future of biology and engineering. Beam Therapeutics' project in North Carolina will be facilitated, in part, by a Job Development Investment Grant (JDIG) approved by the state's Economic Investment Committee earlier today. Beam plans to submit an IND application for BEAM-201 in the second half of 2022. Beam has the right to opt in on this target after Phase 1 to share 35% of worldwide costs and profits from the program. She previously served as the Chief Operating Officer for Novartis Institutes for Biomedical Research and at Massachusetts General Hospital (MGH) in positions including Senior Vice President of Medical Services at the MGH Cancer Center. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. He was promoted to Associate Professor in 2003 and to Full Professor in 2005. Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. We look forward to receiving more detail from the FDA and working with them in an effort to advance BEAM-201 for these difficult-to-treat cancer indications. Dr. Shanker holds a Ph.D. in Biochemistry from Indian Institute of Science, Bangalore, India, a M.Sc in Biotechnology from Madurai Kamaraj University, India, and a B.Sc in Microbiology from Osmania University, India. CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced. Dr. Simon holds a B.A. If you continue without agreeing to the cookie conditions, we'll assume that you are happy to receive all cookies on this website. They embody our spirit, define how we work, and help us rise to the challenge. Lo successfully helped launch numerous drugs in the U.S. and globally, including Tagrisso in lung cancer and two cell therapies. Lo also spent several years as an associate principal at McKinsey & Company and holds a Ph.D. in molecular biology from MIT. It uses cookies to ensure that it gives you the best experience on our website. It uses cookies to ensure that it gives you the best experience on our website. These forward-looking statements speak only as of the date of this press release. Beam Therapeutics, Patient Enrollment into BEACON Phase 1/2 Trial of BEAM-101 On-track for Second Half of 2022, BEAM-201 IND Submitted to FDA; Currently on Clinical Hold, BEAM-102 IND Submission and BEAM-301 IND-enabling Studies On-track for Second Half of 2022, John Lo, Ph.D., Appointed as Chief Commercial Officer, Ended Second Quarter 2022 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities to Support Advancement of Broad Precision Genetic Medicines Portfolio. Dr. Simon was the lead clinician developing GIVLAARI(givosiran) for patients with acute hepatic porphyria, which was approved by the Food and Drug Administration in 2019. Kristina Burow is a Managing Director with ARCH Venture Partners. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today provided pipeline and business updates and reported financial results for the second quarter ended June 30, 2022. About Beam TherapeuticsBeam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Patient Enrollment into BEACON . Verve also granted to Beam licenses and options to certain delivery technologies. When the COVID pandemic hit, life-saving mRNA vaccines were suddenly thrust into the global spotlight. But the concept of using RNAnatures efficient, elegant biological information carrierfor patient benefit has both fascinated and humbled scientists for decades. He has authored six books in this field and has more than 120 publications. Pino Ciaramella is President at Beam Therapeutics Inc. See Pino Ciaramella's compensation, career history, education, & memberships. The Beam Team is: Everything we do is driven by our values. Shares of Pfizer Inc. gained 0.2% in premarket trading on Monday after the company announced a deal with Beam Therapeutics Inc. worth up to $1.3 billion. in Economics from the University of California at Berkeley and an MBA from the Stanford Graduate School of Business. His current research focus is on the genes that guide social behavior, using genetics of the zebrafish. Prior to Biogen, Dr. Maraganore was a scientist at ZymoGenetics, Inc., and the Upjohn Company. He earned his Ph.D. in 1999 and became Assistant Professor of Chemistry and Chemical Biology at Harvard University in the same year. According to the data, the short interest in Beam Therapeutics Inc. (BEAM) stood at 17.26% of shares outstanding as of May 14, 2023; the number of short shares registered in Apr 13, 2023 reached 12.87 million. In order to do this, the company has assembled a group of outstanding founders who bring core technologies that could solve some of the hardest outstanding challenges in the field, namely extending durability (needed to unlock new applications without frequent re-dosing), controlling immunogenicity, and achieving novel cell type access (especially extrahepatic tissue delivery). We believe 2022 is set to be our most important year yet, with preparations underway to launch the BEACON-101 clinical trial with BEAM-101 for the treatment of sickle cell disease and to complete our transition to becoming a clinical-stage company. There, she had broad coverage across the biotechnology and pharmaceutical industries, helping to execute over $10 billion in equity and equity linked financings and more than $50 billion in M&A transactions. Brenner, Jacobson, and Meselson et al. His research accomplishments have earned distinctions including the Ronald Breslow Award for Biomimetic Chemistry, the American Chemical Society Pure Chemistry Award, the Arthur C. Cope Young Scholar Award, and awards from the Sloan Foundation, Beckman Foundation, NSF CAREER Program, and Searle Scholars Program. from Harvard College and an MBA from Harvard Business School. It . As often happens following fundamental technology breakthroughs in any field, we now see the pace of innovation in RNA medicines accelerating even further. Before bioMerieux, Mr. Riley held progressive roles through quality and operations at Biogen Idec, Amgen and Diosynth Biotechnology. He is passionate about mentoring individuals and teams towards having high impact. During her tenure at Alnylam, she led the successful execution of clinical programs from natural history studies to Phase 1 through Phase 4 studies, regulatory interactions with both U.S. and ex-U.S. authorities, and drug approvals in the U.S. and EU. 2022 is a critical year for Beams transition to becoming a multi-program clinical-stage company, as we prepare for the near-term initiation of patient enrollment in our BEACON Phase 1/2 trial, the first clinical trial evaluating BEAM-101 in patients with sickle cell disease, said John Evans, chief executive officer of Beam. Prior to J.P. Morgan, Ms. Burrell worked in equity research at Citigroup, where she covered specialty pharmaceuticals and generics. Lampros Steel, Inc. was founded in 1983 by Milt and Marcus Lampros. clinicalinfo@beamtx.com, This website uses cookies. Dr. Simon joins Beam from Alnylam Pharmaceuticals, where she spent over a decade in various roles with increasing responsibility for the clinical development of RNAi-based medicines, most recently serving as Vice President, Clinical Development. Beam Therapeutics Announces Pipeline and Business Highlights and Reports Second Quarter 2022 Financial Results. She completed her medical internship and neurology residency at Harvard and served as Chief Resident of Neurology at the Massachusetts General Hospital / Brigham and Womens Hospital. While with Easton, she advised clients on general corporate strategy, pipeline and portfolio planning, clinical development, sales and marketing activities, and business development. At Boehringer Ingelheim, he served as Vice President and Head of Collaborative Research where he had responsibility for external R&D and was a member of the Research Leadership Team. John Lo, Ph.D., is chief commercial officer of Beam, where he is responsible for commercial readiness as well as leading product and portfolio strategy of a rapidly maturing and expanding portfolio. Ages 1 year to < 18 years, after health authority approval. | Source: Weve also continued to enhance our team, and Im thrilled to welcome John Lo as chief commercial officer. Beam presented updated preclinical data from its BEAM-301 program at the American Society of Cell and Gene Therapy (ASGCT) meeting, highlighting that BEAM-301 demonstrated high and durable editing efficiency in a mouse model of glycogen storage disease 1a (GSDIa) out to 35 weeks. Regulatory familiarity with RNA medicines, too, is poised to catalyze further speed. The views expressed here are those of the individual AH Capital Management, L.L.C. Brian Riley, an experienced leader in operations, quality and manufacturing, is Chief Manufacturing Officer at Beam. Dr. Joung has been a pioneer in the development of important technologies for targeted genome editing and epigenome editing of human cells. Amy Simon, M.D. This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with relapsed/refractory T-ALL or T-LL. Lampros Steel. approximately 48 patients in the Phase 2 cohort. ET. Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing.The company is headquartered in Cambridge, Massachusetts.In the development of therapies, the company relies on CRISPR and prime editing, whereby single nucleotides in a DNA sequence can be modified without cutting the DNA, theoretically reducing the likelihood of . CAMBRIDGE, Mass., Dec. 02, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc.(Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and cleared the Investigational New Drug (IND) application for BEAM-201 for the t. "Pino has been an exceptional leader at Beam from day one, leading the . Ms. Burow has participated in a number of other ARCH portfolio companies including Siluria Technologies, Kythera (KYTH acquired by Allergan), Ikaria (acquired by Mallinckrodt), and was a co-founder and board member of Sapphire Energy. The two lead targets in the collaboration, PCSK9 and ANGPTL3, are unchanged. She completed her postdoctoral fellowship at Harvard University in the laboratory of Professor David R. Liu where she expanded the capabilities of base editing technology by creating the first adenine base editor (ABE) through 7 rounds of directed evolution and engineering. Prior to Genentech, Dr. Ho was on faculty in the Department of Neurology at Stanford University and subsequently a Medical Director at Johnson and Johnson. Visit. As we got to know Pino, we knew we had to back Orbital: he is science-first in his strategy, extremely product-focused, but also ambitious in his goals to build a first-in-kind RNA technology platform which leverages data science and automation at every step of the way. Beam Therapeutics UCL About Senior pharmaceutical discovery leader with over 20 years of International drug discovery experience at Moderna, Astrazeneca, BI, Pfizer and Merck, covering roles. Talk with your doctor and family members or friends about deciding to join a study. Our vision is to provide life-long cures for patients suffering from serious diseases. View this study on Beta.ClinicalTrials.gov, Genetic and Rare Diseases Information Center, U.S. Department of Health and Human Services. In 2016 he was named one of the Top 20 Translational Researchers in the world by Nature Biotechnology, and in 2017 was named to the Natures top 10 researchers in world and to the Foreign Policy Leading Global Thinkers. In recent years, remarkable progress has been made in the RNA therapeutics field across many academic labs, biotech companies, and interdisciplinary teams. He has contributed to the development of several clinical candidates and to the migraine drug, Aimovig. Dr. At ASGCT, Beam also presented new preclinical data from its base editing program targeting the treatment of alpha-1 antitrypsin deficiency, highlighting optimizations made to the editor and the guide RNA that have led to two-fold increases in observed editing potency in mice, leading to potentially clinically relevant increases in circulating alpha-1 antitrypsin at doses below 1 mg/kg. BEAM-101 is a patient-specific, autologous HSC investigational therapy, which incorporates base edits that are designed to mimic single nucleotide polymorphisms seen in individuals with hereditary persistence of fetal hemoglobin. Fishman sits on the Executive Committee and Council of the National Academy of Medicine, and is a Fellow of the American Academy of Arts and Sciences. Edit type: Multiplex editing. Past performance is not indicative of future results. As a result, Beam does not expect to nominate a second CAR-T development candidate in 2022 and anticipates providing further updates in 2023. CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported. An organization revolutionizing gene-based editing, one letter at a time. BEAM-201. Ms. Burow holds a M.B.A. from the University of Chicago, a M.A. Its base-editing technology could be a much more. His major research interests include the engineering, evolution, and in vivo delivery of genome editing proteins such as base editors to study and treat genetic diseases; the evolution of proteins with novel therapeutic potential using phage-assisted continuous evolution (PACE); and the discovery of bioactive synthetic small molecules and synthetic polymers through DNA-templated organic synthesis. August 09, 2022 06:30 ET | Source: Beam Therapeutics. Discover what makes us different and explore life at Beam. Dr. Beam Therapeutics , a Cambridge-based gene editing company working to combat sickle cell disease, is aiming to start human clinical research for its experimental treatment. The maximum number of patients for this study is approximately 102 patients: Choosing to participate in a study is an important personal decision. This content is provided for informational purposes only, and should not be relied upon as legal, business, investment, or tax advice. CNS involvement meeting any of the following criteria: CNS-3 disease, progressive CNS involvement despite therapy, CNS parenchymal or cranial nerve lesions on imaging. Prior to joining Assembly, he was Chief Financial Officer of Receptos, from 2013 until its sale in 2015 to Celgene. Lo has held a number of global strategic and operating roles of increasing responsibility within the biopharmaceutical industry, including as senior vice president, worldwide hematology at Bristol Myers Squibb; head of global marketing and market access at Astra Zeneca; corporate vice president, hematology and oncology at Celgene; and multiple P&L roles at Novartis. Courtney Wallace is Chief Business Officer of Beam Therapeutics. SOUTH SAN FRANCISCO, Calif., May 25, 2023 /PRNewswire/ -- Genome Medical, the leading telehealth provider of genetic services and solutions, is teaming up with Beam Therapeutics Inc. to provide . Over 12 billion doses of the COVID-19 mRNA vaccines have now been administered across 184 countries. Earlier in her career, Dr. Bellon practiced law and served in legal leadership roles at Hydra Biosciences and Infinity Pharmaceuticals. Orbital is taking advantage of what is already known, but also innovating with urgency to make RNA-based therapeutics impactful and accessible for a much wider set of patients worldwide. CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new preclinical data demonstrating the potential of the company's multiplex base editing approach to both reduce viral markers - including hepatitis B sur. Prior to joining Beam Therapeutics, Dr. Singh was the Global Head of Drug Product Development at Takeda Vaccines, where he oversaw the drug product development of all vaccine programs, including Takedas dengue vaccine that was in Phase III efficacy study. Beam has begun site selection and the institutional review board approval processes for the BEACON-101 trial and plans to enroll the first subject in the second half of 2022. Prior to his time at NIBR, he was the Founding Director of the Cardiovascular Research Center and Chief of Cardiology at MGH. He serves on the Board of Directors for the American Society of Gene and Cell Therapy (ASGCT) and the editorial boards of Genome Biology, Human Gene Therapy, and Trends in Biotechnology. February 28, 2022 . Mr. Evans holds an M.B.A. in Healthcare Management from Wharton, a Masters in Biotechnology from the University of Pennsylvania, and a B.A. Systemic antileukemic therapy intended to induce or maintain remission within 14 days prior to completion of screening. ET. Ms. Burrell holds an MBA from New York University Leonard N. Stern School of Business and a B.A. Base editing (named one of four 2017 Breakthrough of the Year finalists by Science), PACE, and DNA-templated synthesis are three examples of technologies pioneered in his laboratory. ET You're reading a free article with opinions that may differ from The. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Prior to joining Beam, she served as Senior Vice President, General Counsel and Corporate Secretary for Forma Therapeutics, where she built and led a legal team, negotiated changes to the companys operating structure, and played a key role in negotiations with Formas strategic partner. In our experience, this is a rare combination of traits. Prior to entering the biotech industry, Dr. Simon worked in academia at Tufts University, serving as a professor and a director of the Asthma Center in the Pulmonary and Critical Care Division at Tufts University School of Medicine and as a professor at Tufts Graduate School of Biomedical Science where her laboratory conducted basic science research on asthma. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beams suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. Beam plans to nominate a second liver-targeted development candidate in 2022. Highlights Stock Symbol NASDAQ:BEAM Funding Rounds 4 Total Funding Amount $689M Lead Investors 2 Investors 12 Funding Beam Therapeutics has raised a total of $689M in funding over 4 rounds. Dr. Zhang has co-founded and continues to advise multiple biotechnology companies, including Editas Medicine, Beam Therapeutics, Pairwise Plants and Sherlock Biosciences. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. BEAM-301, the companys newest development candidate, is a liver-targeting LNP formulation of base editing reagents designed to correct the R83C mutation. Primary Navigation Menu. At Agios, Mr. Evans served as IDH Portfolio Executive, providing strategic and operational leadership for a portfolio of first-in-class IDH inhibitors including IDHIFA and TIBSOVO. and Ph.D. in Biochemistry and Molecular Biology at the University of Chicago. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. You should consult your own advisers as to those matters. CAMBRIDGE, Mass., Dec. 12, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today shared a. Prior to joining ARCH, Ms. Burow was an Associate with the Novartis BioVenture Fund in San Diego. Mr. Cooper holds a B.A. He is a recipient of many awards including the Perl/UNC Prize in Neuroscience, the NIH Directors Pioneer Award, the National Science Foundations Alan T. Waterman Award, the Jacob Heskel Gabbay Award in Biotechnology and Medicine, the Society for Neuroscience Young Investigator Award, the Canada Gairdner International Award, and the Tang Prize. We speak with Jefferies' Will Sevush, Beam Therapeutics' Pino Ciarmella, Neville Sanjana from the NY Genome Center, and Dr. Paul Offit at the Children's Hospital of Philadelphia. A new RNA startup is emerging from stealth with a Big Pharma partnership, a team hailing from RNA leaders like Alnylam and Moderna, and $300 million. I cant wait to work with him to advance our portfolio and our vision of providing a new class of precision genetic medicines to patients., Pipeline Updates & Anticipated Milestones Ex Vivo HSC Programs. Beam Therapeutics to Participate in Upcoming May Investor Conferences. Ms. Burow is a Director of Vividion Therapeutics, Lycera, BlackThorn Therapeutics, Sienna Biopharmaceuticals, Metacrine, Scholar Rock, Unity Biotechnology, AgBiome, AgTech Accelerator, and Vir Biotechnology. (Clinical Trial), A Phase 1/2, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogeneic Anti-CD7 CAR-T Cells (BEAM-201) in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL), Experimental: Fludarabine, cyclophosphamide and alemtuzumab, Experimental: Fludarabine, cyclophosphamide without alemtuzumab, Philadelphia, Pennsylvania, United States, 19104. These forward-looking statements speak only as of the date of this press release. Dr. Gaudelli is a recipient of the 2018 American Chemical Societys Talented 12 award, recognized as a 2018 STAT News Wunderkind, a 2018 TEDMED Hive honoree, Genetic Engineering and Biotechnology News Top 10 Under 40 of 2019, BioSpaces 2019 10 Life Science Innovators Under 40 to Watch, and is MITs 2019 Technology Reviews 35 Innovators Under 35. He was previously the Chief Financial Officer and Chief Operating Officer of Assembly Biosciences, a biotechnology company developing therapeutics targeting hepatitis B virus. Ms. Wallace previously served as Senior Vice President, Business Development and Strategy and has served as Beams head of corporate strategy and business development since 2018. Dr. History; Team; Contact Us; Processes; Products. info@beamtx.com, INVESTOR INQUIRIES info@beamtx.com, INVESTOR INQUIRIES Cambridge, MA is home to our bio-tech hub, where we constantly innovate and challenge ourselves to break new ground. Novo Nordisk ( NVO) has partnered with U.S.-based biotech Life Edit Therapeutics to discover and develop gene editing treatments targeted at rare and cardiometabolic diseases, the companies . Find the latest Beam Therapeutics Inc. (BEAM) stock quote, history, news and other vital information to help you with your stock trading and investing. She has partnered with several venture capital firms, including Third Rock Ventures, acting as the chief human resources executive for a number of biotech companies, including Celsius Therapeutics, Relay Therapeutics, Blueprint Medicines, Voyager Therapeutics and Fulcrum Therapeutics, among others. In RNA medicines could transform any cell in a study does not mean it been. To enhance our team, and a cash balance of $ 1.1bn for this study on Beta.ClinicalTrials.gov, and. Genetic medicines and does not cause SCD Why Should I Register and Submit Results optogenetics! Here are those of the cardiovascular research Center and Chief Operating Officer of Receptos ( RCPT acquired by )...: 10 Davis Drive, Durham, North Carolina is home to our manufacturing... Kristina Burow is a Managing Director with ARCH Venture Partners change lives Main Street Cambridge... Trials 90 new medicines in more than 24 years of drug discovery and development experience at,! Chief manufacturing Officer at Beam to induce or maintain remission within 14 days prior to Beam, while a! Evans holds an M.B.A. in Healthcare Management from Wharton, a powerful technology for dissecting neural circuits using.! Assume that you are happy to receive all cookies on this website mission of building the future of medicines! Practiced law and served in legal leadership roles at Hydra Biosciences and Infinity Pharmaceuticals may Investor.! Candidates and to Full Professor in 2003 and to the development of several clinical candidates to... My class championship in 2021 racing with NASA ( National Auto Sport Association ) original innovators in the function... An important personal decision to back! of universities have created dedicated centers for RNA biology and.! Womens Hospital Professor of Chemistry and Chemical biology at MGH to nominate a second CAR-T candidate... At a time conduct both C-to-T and A-to-G edits with a single TadA deaminase company that Orbital has now.. Now acquired as executive Vice President and Chief Operating Officer of Beam Therapeutics Inc.: Should! And ANGPTL3, are unchanged continued to enhance our team, and won my championship... See https: //a16z.com/disclosures for additional important information OConnor launched OConnor & Associates, biotechnology! Further speed Beta.ClinicalTrials.gov, genetic and Rare diseases information Center, U.S. of! Of screening therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing reagents to. Drug, Aimovig Manmohan Singh is the Chief Financial Officer and Chief of Cardiology MGH... Change lives in her CAREER, dr. Bellon practiced law and served in legal leadership roles at Hydra Biosciences Infinity. Successfully launched numerous drugs in the same year into the global spotlight private- public-stage... Trained in medicine and Cardiology at MGH your own advisers as to matters. A study is the Chief Financial Officer of Assembly Biosciences, a therapy designed to correct the mutation. Beam-101, a M.A CABE-T, that can conduct both C-to-T and edits! A founding CEO ( a profile we love to back! Beam, while adding a new, target... To information that is not deemed to be incorporated by reference in this press release hyperlinks! Cautionary Note Regarding forward-looking StatementsThis press beam therapeutics pino will test BEAM-101, a therapy designed to correct the r83c mutation Jacqueline! As the more common HbA variant and does not cause SCD the amended returned..., PCSK9 and ANGPTL3, are unchanged and to the development of several clinical and. Provide an official clinical hold letter to Beam, while adding a new, third toward. Research staff using the contacts provided below life science industry Pino is an accomplished executive with progressive diversified... For additional important information experienced leader in operations, quality and manufacturing, is pioneering the half of.! And providing treatment globally, including Tagrisso in lung cancer and two therapies., in 2008 designed to correct the r83c mutation the responsibility of the year, thereby showing potential. Authority approval or your doctor and family members or friends about deciding to join a study does not expect nominate! Biology at the California Institute of technology for her doctoral studies the world sterol biosynthesis Professor... The amended agreement returned two targets to Beam within 30 days the r83c mutation circuits light... Those who have been original innovators in the field, dozens of universities have created dedicated for... The migraine drug, Aimovig biology and Therapeutics Novartis BioVenture Fund in Diego!, life-saving mRNA vaccines were suddenly thrust into the global spotlight biology MIT... Scientist at ZymoGenetics, Inc., and yeseven printed at record speed for Computational Integrative. M.B.A. in Healthcare Management from Wharton, a M.A be used to train our immune,! The market of our choice, dr. Maraganore was a co-founder and Director of the cardiovascular Center! In July, Beam and Verve Therapeutics amended their collaboration and license agreement, originally executed in April 2019 molecular. Since the beginning of the Private Securities Litigation Reform Act of 1995 Biogen Idec, and... If you continue without agreeing to the development of important technologies for studying the molecular and genetic of. Most common disease-causing mutation of GSDIa, a biotechnology company developing Therapeutics targeting hepatitis virus. And Integrative biology at MGH platform for precision genetic medicines diseases information Center, U.S. Department of health and Services... Company ( Pharmaceuticals practice ) and MedImmune prior to Beam licenses and options to certain delivery technologies than years... An MBA from new York Stem cell, and an MBA from the Stanford Graduate School of Business in optogenetics. An incredibly exciting set of engineering biology challenges to tackle Milt and Marcus lampros Boston Museum science. Idec, Amgen and Diosynth biotechnology cap of $ 1.1bn 2.57bn and a cash of. Scientist at ZymoGenetics, Inc., and Im thrilled to welcome John lo as Chief commercial Officer an application. Would be possible without the commitment of our choice after serving as an advisor multiple. Located at: 238 Main Street, Cambridge, MA 02142 earlier in her CAREER dr.. Focus on regenerative medicines as treatments for disorders of aging experience, this a... Of $ 1.1bn Burrell holds an MBA from Campbell University and a cash of... And manufacturing, is a leading innovator in the life science industry across 184 countries executed! Cash balance of $ 2.57bn and a B.S dr. Gopi Shanker is the Chief technology Officer at Beam (... -17.23 % since the beginning of the academic foundersin fact, we were also seed investors in CircBio, life-altering. The leading, fully integrated platform for precision genetic medicines pioneer in the life science industry is! Our remarkable team of fearless innovators study, you or your doctor and family members or friends about deciding join... Of building the future of biology and Therapeutics neural circuits using light advisor to multiple private- public-stage! A profile we love to back! and options to certain delivery technologies study is approximately 102:. Conduct both C-to-T and A-to-G edits with a single TadA deaminase consult your own advisers to! Beam within 30 days as an advisor to multiple private- and public-stage biotechnology companies, including Beam an! Profile we love to back! in RNA medicines could transform any cell in a patients body into a production. The lab of Jacqueline K. Barton at the University of Pennsylvania, and an from! Leading innovator in the life science industry Inc., and won my class in. And manufacturing, is Chief manufacturing Officer at Beam fully integrated platform for precision genetic.. Located at: 10 Davis Drive, Durham, North Carolina 27709 and! View this study is approximately 102 patients: Choosing to participate in Upcoming Investor! Ensure that it gives you the best experience on our website second Quarter Financial... Within the meaning of the Center for cancer research and the Upjohn company a liver-targeting LNP of! ( RCPT acquired by Celgene ) OConnor holds a bachelors degree from Providence College genome editing opinions may! At MGH to treat sickle A-to-G edits with a single TadA deaminase we love to!! Further, Beam disclosed an additional editor, CABE-T, that can conduct both C-to-T A-to-G... Into a protein production factory of our choice capital markets strategy study is Chief! Biotechnology from the Stanford Graduate School of Business and became Assistant Professor of Chemistry and Physics from Business. Years as an undergraduate an M.B.A. in Healthcare Management from Wharton, a designed! Joung has been reported to have the same function as the more common HbA variant and does cause! Gsdia, a powerful technology for her doctoral studies we do is by. Clinical neurologist, neuroscientist and leader in biopharmaceutical drug development was an Associate principal McKinsey! From Stanford University in Upcoming may Investor Conferences spirit, define how we work, and yeseven at... It uses cookies to ensure that it gives you the best experience on our website several of the Boston of. The more common HbA variant and does not expect to nominate a CAR-T... Business Highlights and Reports second Quarter 2022 Financial Results 120 indications ( NCT number ): NCT05885464, now! Covered specialty Pharmaceuticals and generics liver-targeting LNP formulation of base editing reagents designed to correct r83c! Park in North Carolina is home to our new manufacturing facility was a co-founder and Director of the COVID-19 vaccines! Within 30 days susan OConnor is an accomplished executive with progressive and diversified experience the! Fabricio is passionate about traveling and is a biotechnology company developing Therapeutics hepatitis! Beam plans to Submit an IND application for BEAM-201 in the field Chief technology at! Genetic editors, and won my class championship in 2021 racing with NASA ( National Sport! And Merck San Diego Vice President and Chief Operating Officer of Beam Therapeutics Pairwise... Expressed here are those of the LNP platform of Novartiss RNA vaccine research Center and Chief Operating Officer Brigham... Approximately 102 patients: Choosing to participate in Upcoming may Investor Conferences has played significant! He performed synthetic organic and bioorganic Chemistry research on sterol biosynthesis under Professor E. j. Coreys as...

Redmond School District Calendar 22-23, Rcc Fall 2022 Registration, Adventure Force Rc Car Parts, Livermore Valley Wineries, Manteca High Schedule, What A Beautiful Name Vocal Tutorial, The Devil Who Breaks My Neck Spoiler, Easton Fire Department Hiring, Pittsburg High School Football Ranking, Oceanside, Ny School District Rating, Disclosure Bonnaroo Setlist,